Telix Pharmaceuticals Ltd. (AU:TLX) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Telix Pharmaceuticals Limited has submitted a Biologics License Application to the U.S. FDA for TLX250-CDx, a PET agent designed for the non-invasive diagnosis of kidney cancer. If approved, it would be the first targeted PET imaging agent for kidney cancer available in the U.S., highlighting Telix’s expanding presence in the urology imaging market. Investors might find this development promising as the company aims for a commercial launch in 2025.
For further insights into AU:TLX stock, check out TipRanks’ Stock Analysis page.